Skip to content

Performance and Safety Evaluation of the S360 Medical Device Software.

Evaluation of the Performance and Safety of the S360 Medical Device Software.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05522595
Acronym
ArgoS360
Enrollment
200
Registered
2022-08-31
Start date
2023-11-02
Completion date
2024-01-02
Last updated
2023-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Binocular Eye Movement Disorder, Binocular Vision Disorder, Ocular Motion; Disorder

Keywords

Eye tracker, Orthoptics analysis, Neuro-visuo-motor analysis, Eye movement

Brief summary

The aim of this interventional, cross-sectional study is to evaluate the performance and the safety of the medical device software S360. This clinical investigation is performed in order to demonstrate the conformity of the medical device, when operating under the normal conditions of its intended use, in accordance with the General Safety and Performance Requirements pertaining to clinical evaluation of the device regarding the Medical Device Regulation (MDR) 2017/745 (EU).

Detailed description

Background: Accurate detection and interpretation of eye movement abnormalities often guides differential diagnosis and discussions on prognosis. Therefore, adequate diagnosis permits to direct treatment of disabling visual symptoms and signs. A comprehensive clinical eye movement examination is high yield from a diagnostic standpoint; however, skilful recording and quantification of eye movements can increase detection of subclinical deficits, confirm clinical suspicions, guide therapeutics, and generate expansive research opportunities. Recently, many technologies, allowing objective measurements, have been developed. The most commonly used eye movement measurement technique is the high frequency video camera (Eye tracker). In this context, SIERRA NEUROVISION has developed the S360, a medical device software using the infrared video-oculography technology. It is intended to collect data for orthoptics and neuro-visuo-motor analysis. It records the patient's eye movements, displays the patient's scoring next to normative values retrieved from literature and widely used in the current practice. Design: The study is cross-sectional, interventional, open label, single-arm, comparative and single-center study. This study is a pre-marketing, confirmatory research which is performed in order to evaluate the performance and the safety of S360 MDSW compared to the standard of care procedure. Intervention: As the current study is cross-sectional, no follow-up visits related to the study are planned. All study procedures will be carried out during the inclusion visit which will take place during the patient's medical visit as part as his/her standard of care. The study will be conducted in two parts: Part 1 : standard of care measurements. * CISS (Screening for convergence insufficiency) questionnaire completion * Eye movements measurements using the standard tools used by the orthoptist (a prism bar, a penlight and a video projector, etc). A first diagnosis based on the interpretation of the results provided by the standard of care measurements will be established by a first evaluator (orthoptist). Part 2: S360 measurements \- Eye movements measurements using the medical device software S360. A second diagnosis based on the interpretation of the outcomes provided by the MDSW S360 will be established by a second evaluator (orthoptist). The two measurements procedures are performed in two different examination rooms by two different operators. The diagnoses are established by two different investigators (orthoptist).

Interventions

DEVICES360

In the first part of the intervention, after the CISS questionnaire completion by the patient, participant's eyes movements measurement will be performed using the reference procedure (standard of care). A first diagnosis is established according to the interpretation of the results by a first evaluator. In the second part of the intervention, the participant's eyes movements will be measured using the medical device S360. A second diagnosis is established according to the interpretation of the software's displayed data by a second evaluator.

Sponsors

Institut des Sciences de la Vision
CollaboratorUNKNOWN
CEISO
CollaboratorINDUSTRY
Sierra Neurovision
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
6 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient ≥ 6 years old requiring an orthoptic or neuro-visual assessment in order to assess the effectiveness of oculomotor skills; * Both gender; male and female * Symptomatic or non-symptomatic patient; * Affiliated person or beneficiary of a social security scheme, * Free, informed and written consent signed by the participant and the investigator for adults or by parents/legal representative for patients aged from 6 to 17years old

Exclusion criteria

* Visual acuity below 5/10 not improvable * Patient with a head injury; * Patient with ocular injury; * Patient with diagnosed serious pathologies that may interfere with the study measurements; * Patient with medical treatment that may interfere with the study * Patient with hypersensitivity to electronic devices; * Non-cooperative patient (e.g. restless patient); * Non-French speaker patient; * Patient unable to understand study procedures; * Subject who has forfeited their freedom by administrative or legal award, or is under guardianship or under limited judicial protection; * Patient refusing to participate in the study.

Design outcomes

Primary

MeasureTime frameDescription
Sensitivity (Se) and specificity (Sp)Day 0Sensitivity (Se) and specificity (Sp) of performed diagnosis using recorded data from the S360 versus performed diagnosis with standard measurement

Secondary

MeasureTime frameDescription
Repeatability of the S360's measured dataDay 0Coefficient of variation calculation of the S360's measured data
Reproducibility of the S360's measured dataDay 0The reproducibility coefficient of the S360's measured data
Evaluation of the usefulness of the MDSW S360 in the current practiceDay 0Rate of positive feedback estimation
Validation of the technical functionalities of the MDSW S360Day 0Calculation of the : * Rate of successful outcomes transmission * Rate of successful display of outcomes measurement * Rate of successful report generation * Rate of successful report transmission
Accuracy of the S360's measured dataDay 0Error rate calculation of the S360's measured data
Operator's comfort of using the medical device S360Day 0Operator's comfort of using the medical device and the headset survey Comfort level will be expressed by the rate of satisfaction: Higher rate means a better Comfort
Comparison of the duration of the two procedureDay 0Average duration of the two procedures (S360 vs Standard of care)
Patient satisfactionDay 0Patient's satisfaction level by using a satisfaction survey Satisfaction level will be expressed by the rate of satisfaction: Higher rate means a better satisfaction
Safety : Adverse eventsDay 0Incidence of the medical device's related-adverse events estimation

Countries

France

Contacts

Primary ContactLionel Moiroud
lionel.moiroud@sierra-neurovision.com(+33) 7 82 75 37 79

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026